MindBio Therapeutics (CVE:MBIO) | WebDisclosure

Basculer en Français

9871	Companies
198452	Keywords
129509	Articles
105554	Press releases

Home
Companies
MindBio Therapeutics

PRESS RELEASE

published on 03/20/2024 at 09:50, 1 year 10 months ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression

MB22001 Major Depressive Disorder Phase 2b MindBio Psychedelic Treatment
PRESS RELEASE

published on 03/20/2024 at 09:50, 1 year 10 months ago

MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results

Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRIEF

published on 03/04/2024 at 11:05, 1 year 11 months ago

MindBio Therapeutics passe à l'essai de phase 2B pour la médecine psychédélique dans le trouble dépressif majeur

MindBio Thérapeutique Trouble Dépressif Majeur Essai Clinique De Phase 2B Médecine Psychédélique Microdosage Du LSD
BRIEF

published on 03/04/2024 at 11:05, 1 year 11 months ago

MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder

Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
PRESS RELEASE

published on 03/04/2024 at 11:00, 1 year 11 months ago

MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp

Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
BRIEF

published on 02/26/2024 at 10:30, 1 year 11 months ago

MindBio annonce des résultats positifs dans un essai clinique de microdosage à domicile pour la dépression

Depression MB22001 Essai Clinique MindBio Microdosage
BRIEF

published on 02/26/2024 at 10:30, 1 year 11 months ago

MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression

Depression MB22001 MindBio Microdosing Clinical Test
PRESS RELEASE

published on 02/26/2024 at 10:30, 1 year 11 months ago

MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks

Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
PRESS RELEASE

published on 02/14/2024 at 10:00, 2 years ago

MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development

MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
PRESS RELEASE

published on 01/30/2024 at 08:10, 2 years ago

MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions

MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD

Accesswire

Published on 02/16/2026 at 15:30, 2 hours 47 minutes ago

Sarama Announces Change of Auditor
Published on 02/14/2026 at 01:00, 2 days 17 hours ago

Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:30, 2 days 19 hours ago

Norse Gold Corp. Announces New Director
Published on 02/13/2026 at 22:15, 2 days 20 hours ago

Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 3 days ago

Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold

View all ACCESSWIRE

EQS Group

Published on 02/16/2026 at 17:46, 30 minutes ago

Key Figures 15.02.2026
Published on 02/16/2026 at 17:45, 31 minutes ago

FIGEAC AÉRO: NOUVELLE AVANCÉE DE FIGEAC AÉRO SUR LE MOTEUR DU RAFALE
Published on 02/16/2026 at 17:45, 31 minutes ago

FIGEAC AÉRO: NEW DEVELOPMENT FOR FIGEAC AÉRO ON THE RAFALE ENGINE
Published on 02/16/2026 at 17:45, 32 minutes ago

Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
Published on 02/16/2026 at 16:30, 1 hour 46 minutes ago

Schweizer Electronic AG: Change in the Executive Board

Les Echos

Published on 02/16/2026 at 17:45, 32 minutes ago

Cegedim : Déclaration d'actions et de droits de vote au 31 janvier 2026
Published on 02/16/2026 at 17:45, 32 minutes ago

COGRA : RÉSULTATS SEMESTRIELS 2025/26
Published on 02/16/2026 at 17:43, 34 minutes ago

Aéroports de Paris S.A - Trafic du mois de Janvier 2026
Published on 02/16/2026 at 17:43, 34 minutes ago

Aéroports de Paris S.A - January 2026 traffic figures
Published on 02/16/2026 at 17:40, 37 minutes ago

Eiffage renforce sa présence en Allemagne avec l’acquisition des actifs de Claus Heinemann Elektroanlagen

View all LES ECHOS COMFI WIRE